Inventiva (IVA) AI Stock Analysis

• Market Cap: $821.09M
• Dividend Yield: N/A
• Average Volume (3M): 75.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: -12.52%
• EPS Growth: -82.84%
• Country: US
• Employees: 114
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.76
• Shares Outstanding: 139,151,280
• 10 Day Avg. Volume: 73,220
• 30 Day Avg. Volume: 75,640
• PEG Ratio: -0.01
• Price to Book (P/B): -1.01
• Price to Sales (P/S): 11.68
• P/FCF Ratio: -1.25
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 29.46
• Enterprise Value/Gross Profit: 29.46
• Enterprise Value/Ebitda: -1.63
• 1Y Price Target: $19.20
• Price Target Upside: 247.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 53 Neutral
• Price Target: $6.00 ▲(8.70% Upside)

Inventiva's overall stock score is primarily impacted by its poor financial performance, which poses significant risks to its long-term sustainability. Despite strong technical indicators suggesting bullish momentum, the company's negative valuation metrics and financial challenges weigh heavily on its attractiveness. The earnings call provided some optimism with strategic developments and financing, but these are overshadowed by operational and financial difficulties.

Positive Factors

Clinical Development Progress

The advancement in the Phase 3 NATiV3 trial for lanifibranor indicates strong progress in clinical development, which is crucial for future product commercialization and revenue generation.

Strategic Partnerships

Strategic partnerships in Japan, South Korea, and China enhance market reach and potential revenue streams, positioning lanifibranor as a leading oral drug in these regions.

Strong Financial Position

A strong cash position and recent financing provide a financial runway to support ongoing clinical trials and operational needs, reducing short-term liquidity risks.

Negative Factors

Financial Instability

The company's financial instability, marked by negative equity and poor cash flow, poses a risk to its ability to sustain operations without continued external financing.

Workforce Reduction

Significant workforce reduction may impact operational capabilities and innovation, potentially delaying product development and commercialization efforts.

Decreased Revenue

A significant drop in revenue highlights challenges in achieving consistent income, which may affect the company's ability to fund its R&D pipeline and operational expenses.

Inventiva Business Overview & Revenue Model

Company Description

Inventiva (IVA) is a clinical-stage biopharmaceutical company focused on the development of orally-available therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases with significant unmet medical needs. The company leverages its proprietary technology platform to develop novel small molecule drugs that target nuclear receptors, transcription factors, and epigenetic modulation.

How the Company Makes Money

Inventiva makes money primarily through the development and commercialization of its drug candidates. As a clinical-stage company, its revenue streams include collaboration agreements, licensing agreements, and milestone payments from partnerships with pharmaceutical companies. These collaborations often involve upfront payments, research funding, and royalties on sales of successfully developed drugs. Additionally, Inventiva may receive government grants or incentives to support its research and development activities. The company is also focused on advancing its pipeline through clinical trials to eventually commercialize its products, which will become a significant revenue stream upon marketing approval.

Inventiva Financial Statement Overview

Summary

Inventiva is facing substantial financial difficulties with persistent losses, negative margins, and significant reliance on external financing. The income statement, balance sheet, and cash flow statement all indicate financial distress, with negative equity and poor cash flow generation.

Income Statement

Inventiva's income statement highlights significant challenges in profitability. The company reports consistent negative net income and EBIT over the years. The revenue growth rate is volatile, with a decrease in the most recent year. Both gross profit and net profit margins are negative, indicating that the company is struggling to cover its costs. EBITDA margin is also highly negative, showcasing operational inefficiencies.

Balance Sheet

Inventiva's balance sheet reveals financial instability with negative stockholders' equity and a high total liabilities figure. The debt-to-equity ratio is not applicable due to negative equity, and return on equity is also negative, reflecting poor returns on shareholders' investments. The equity ratio is negative, further indicating financial distress and a reliance on liabilities.

Cash Flow

The cash flow statement indicates persistent negative operating and free cash flows, suggesting that Inventiva is not generating enough cash from its operations to sustain its business activities. While there is a significant financing cash flow, likely from debt or equity raises, the operating cash flow to net income ratio and free cash flow to net income ratio are weak, pointing towards cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.20M	17.48M	12.18M	4.19M	372.00K
Gross Profit	9.20M	17.50M	17.06M	4.19M	4.42M
EBITDA	-166.53M	-102.04M	-56.29M	-52.76M	-31.77M
Net Income	-184.21M	-110.43M	-54.27M	-49.64M	-33.62M
Balance Sheet
Total Assets	118.97M	69.56M	116.00M	121.98M	138.92M
Cash, Cash Equivalents and Short-Term Investments	96.56M	27.34M	87.78M	86.55M	113.02M
Total Debt	54.33M	37.49M	34.51M	10.12M	10.06M
Total Liabilities	225.61M	101.59M	70.53M	33.12M	27.71M
Stockholders Equity	-106.65M	-32.03M	45.48M	88.87M	111.21M
Cash Flow
Free Cash Flow	-86.26M	-82.15M	-45.49M	-48.16M	-30.88M
Operating Cash Flow	-85.93M	-81.61M	-44.93M	-47.63M	-30.59M
Investing Cash Flow	8.74M	-7.73M	8.87M	-1.79M	-8.56M
Financing Cash Flow	145.59M	29.08M	37.27M	25.45M	111.67M

Inventiva Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVA, the sentiment is Neutral. The current price of 5.52 is below the 20-day moving average (MA) of 5.77, above the 50-day MA of 4.95, and above the 200-day MA of 3.49, indicating a neutral trend. The MACD of 0.29 indicates Positive momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 56.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IVA.

Inventiva Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
URGN	54 Neutral	$788.80M	―	-452.20%	―	10.85%	-1.41%
IVA	53 Neutral	$821.09M	―	344.74%	―	-12.52%	-82.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KURA	47 Neutral	$850.61M	―	-51.11%	―	―	-1.26%
IOVA	46 Neutral	$799.70M	―	-53.16%	―	636.99%	27.10%
MRVI	41 Neutral	$796.73M	―	-55.41%	―	-22.52%	-37.00%
MBX	38 Underperform	$727.07M	―	-56.28%	―	―	―

Inventiva Corporate Events

Inventiva Appoints Andrew Obenshain as CEO to Drive U.S. Market Expansion

On October 1, 2025, Inventiva announced the appointment of Andrew Obenshain as the new Chief Executive Officer, succeeding co-founder Frédéric Cren. This leadership change is part of a strategic move to support Inventiva’s growth, particularly in preparing for potential commercialization in the U.S. market for MASH. Obenshain’s global experience in drug approvals and commercialization is expected to strengthen Inventiva’s position in the MASH field and advance the development of lanifibranor, a promising oral therapy for MASH.

Inventiva S.A. Reports Significant Revenue Growth Amid Rising Losses

On September 29, 2025, Inventiva S.A. released its unaudited financial results for the first half of 2025, revealing a significant increase in revenues to €4,454,000 from €41,000 in the same period last year. Despite this revenue growth, the company reported a net loss of €175,882,000, which is a substantial increase from the previous year’s loss of €49,029,000. The financial update highlights the company’s ongoing challenges in managing its expenses, particularly in research and development and general administrative costs, which have impacted its financial performance.

Inventiva Announces Preliminary First-Half 2025 Financial Results

On July 29, 2025, Inventiva reported its preliminary financial results for the first half of 2025, revealing cash and cash equivalents of €122.1 million and short-term deposits of €24.6 million as of June 30, 2025. The company recorded revenues of €4.5 million, primarily from milestone payments related to its structured financing and licensing agreement with Chia Tai Tianqing Pharmaceutical Group. Inventiva’s net cash used in operating activities increased due to working capital changes and a pipeline prioritization plan. The company anticipates that its current financial resources will support operations until the end of the third quarter of 2026, though additional funds will be needed for long-term objectives.

Inventiva Announces Leadership Changes to Drive Growth

On July 9, 2025, Inventiva announced key leadership changes with the appointment of Jason Campagna as President of R&D and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. These appointments are part of Inventiva’s strategy to drive long-term growth and operational excellence, as the company prepares for the anticipated regulatory submissions and commercialization of lanifibranor, its treatment for MASH. The leadership transition marks a pivotal moment for Inventiva, as it aims to advance its clinical programs and achieve significant milestones in the coming years.